Omitting Completion Dissection in Melanoma? Help is Available for Surgeons Coping Without Routine Dissection, But More Work is Needed

[1]  D. Elder,et al.  Prediction of Residual Nodal Disease at Completion Dissection Following Positive Sentinel Lymph Node Biopsy for Melanoma , 2018, Annals of Surgical Oncology.

[2]  D. Schadendorf,et al.  Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma , 2018, The New England journal of medicine.

[3]  Jeffrey E Gershenwald,et al.  Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[4]  A. Hauschild,et al.  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma , 2017, The New England journal of medicine.

[5]  P. Ascierto,et al.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma , 2017, The New England journal of medicine.

[6]  A. Gesierich,et al.  Completion Dissection or Observation for Sentinel‐Node Metastasis in Melanoma , 2017, The New England journal of medicine.

[7]  C. Berking,et al.  Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. , 2016, The Lancet. Oncology.

[8]  R. Scolyer,et al.  Assessment of a new scoring system for predicting non-sentinel node positivity in sentinel node-positive melanoma patients. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  R. Scolyer,et al.  Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Elashoff,et al.  The Impact on Morbidity and Length of Stay of Early Versus Delayed Complete Lymphadenectomy in Melanoma: Results of the Multicenter Selective Lymphadenectomy Trial (I) , 2010, Annals of Surgical Oncology.

[11]  K. Griffith,et al.  Do Micromorphometric Features of Metastatic Deposits Within Sentinel Nodes Predict Nonsentinel Lymph Node Involvement in Melanoma? , 2008, Annals of Surgical Oncology.

[12]  M. Ross,et al.  Frequency of nonsentinel lymph node metastasis in melanoma , 2007, Annals of Surgical Oncology.

[13]  R. Elashoff,et al.  Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node , 2004, Modern Pathology.

[14]  M. Ross,et al.  Reply to shaw and thompson: “Frequency of nonsentinel lymph node metastasis in melanoma” , 2002 .